文献速递类风湿关节炎脊柱关节炎

评估慢性炎症性风湿病患者心血管风险量表的可靠性

Evaluating the reliability of cardiovascular risk scales in patients with chronic inflammatory rheumatic diseases.
PubMed 文献 · Semin Arthritis Rheum · 2025-02-24

研究在西班牙CARMA项目2080例慢性炎症性风湿病(CIRD)患者中比较QRISK3、SCORE2与PREVENT方程10年心血管病(CVD)风险预测表现。QRISK3与PREVENT-CVD预测全队列平均约10%心血管事件,而SCORE2与PREVENT-ASCVD仅预测平均6.3%。SCORE2、PREVENT-CVD与PREVENT-ASCVD间相关性与可靠性较高,作者认为这些量表在识别高危CIRD患者时可能 largely interchangeable。

要点

  • QRISK3与PREVENT-CVD预测全队列平均约10%心血管事件,SCORE2与PREVENT-ASCVD平均仅6.3%。
  • 各量表两两线性相关系数均高于0.8,平均0.9074,QRISK3与其他量表相关性较低。
  • 识别高危患者时,SCORE2、PREVENT-CVD与PREVENT-ASCVD间kappa指数高于QRISK3与任何其他量表。

核心结论

  • 在随访10年的CIRD患者系列中,SCORE2、PREVENT-CVD与PREVENT-ASCVD之间观察到更高的相关性与可靠性,提示这些量表在识别高危CIRD患者时可能 largely interchangeable。

研究设计与样本

  • 西班牙前瞻性CARdiovascular in RheuMAtology(CARMA)项目队列研究,2010年7月至2012年1月从西班牙67家医院招募类风湿关节炎、强直性脊柱炎与银屑病关节炎患者。
  • 10年随访时评估初始队列全部患者数据,共纳入2080例进行分析,使用招募时记录的数据估算四种10年CVD发病风险评分。

主要发现

  • QRISK3与PREVENT-CVD预测全队列平均约10%心血管事件,而SCORE2与PREVENT-ASCVD预测平均仅6.3%。
  • 各量表两两线性相关系数均持续高于0.8,平均为0.9074,QRISK3与其他量表间相关性较低。
  • 识别高危患者时,SCORE2、PREVENT-CVD与PREVENT-ASCVD间kappa指数高于QRISK3与任何其他量表。
  • 研究提示SCORE2判定为高危的大多数患者,使用PREVENT-CVD或PREVENT-ASCVD时也会被归为高危。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the performance of the QRESEARCH risk estimator version 3 (QRISK3), the Systematic COronary Risk Evaluation (SCORE) 2, and Predicting Risk of cardiovascular disease EVENTs (PREVENT) equationin a cohort of individuals with chronic inflammatory rheumatic diseases (CIRD) enrolled in the Spanish prospective CARdiovascular in RheuMAtology (CARMA) project. METHODS: Between July 2010 and January 2012, the study recruited CIRD patients from 67 hospitals across Spain. It included individuals diagnosed with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. At the 10-year follow-up, data for all patients included in the initial cohort were assessed. We estimated four 10-year cardiovascular disease (CVD) incidence risk scores using data recorded at recruitment. RESULTS: 2080 patients were included in this analysis. QRISK3 and PREVENT-CVD predicted an average of approximately 10 % CV events across the entire cohort, while SCORE2 and PREVENT-Atherosclerotic Cardiovascular Disease (ASCVD) predicted an average of only 6.3 %. The linear correlation coefficients between each pair of scales were consistently above 0.8, with an average of 0.9074. Notably, lower correlations were observed between QRISK3 and the other scales. When identifying patients with higher CV risk, the kappa index was higher between SCORE2, PREVENT-CVD, and PREVENT-ASCVD than between QRISK3 and any other scale. These findings suggest that most patients identified as high-risk by SCORE2 would also be classified as high-risk when using PREVENT-CVD or PREVENT-ASCVD. CONCLUSIONS: The higher correlation and reliability observed between SCORE2, PREVENT-CVD, and PREVENT-ASCVD in our series of CIRD patients followed over a 10-year period suggest that these scales may be largely interchangeable for identifying high-risk CIRD patients.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Llorca J, Ferraz-Amaro I, Castañeda S, et al. Evaluating the reliability of cardiovascular risk scales in patients with chronic inflammatory rheumatic diseases. Semin Arthritis Rheum. 2025. PMID: 40056476. doi:10.1016/j.semarthrit.2025.152694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。